Amylyx Pharmaceuticals Inc.

Home
United States
Cambridge, MA
Amylyx Pharmaceuticals Inc.

Ushering in a new era for treating diseases with high unmet needs

10/22/2025

There are no approved therapies for the approximately 160,000 people in the U.S. who have post-bariatric ( ). That’s roughly 8% of people who have undergone the two most common types of bariatric surgery, Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy, over the last decade. Learn more about this rare condition on our website at https://amylyx.com

10/16/2025

Maria was told she wouldn’t survive another year without bariatric surgery. The procedure saved her life, but a new challenge emerged: post-bariatric hypoglycemia ( ).

At Amylyx, we’re committed to listening to and learning from those living with PBH. In this clip, Maria and her daughter Kelly reflect on the highs and lows of her journey and the hope for treatment. Watch Maria’s full story here: https://bit.ly/47dFpjs

10/14/2025

Our commitment is more than just a promise to work with urgency; it’s a personal responsibility felt by members of like Kelly Sorel. Learn more about our mission and focus: https://amylyx.com/our-company

10/03/2025

is excited to head to the annual Northeast ALS Consortium (NEALS) meeting next week, where we’re presenting a LUMINA clinical trial update and calpain-2 data in ALS. More details below.

10/01/2025

Raquel’s journey with Wolfram syndrome began with a diabetes diagnosis when she was just 4 years old. By age 5, she started losing her vision.

This rare disease affects around 3,000 people in the U.S. and many more globally, but it’s often misunderstood or misdiagnosed.

In honor of Wolfram Syndrome Global Awareness Day ( ), listen to Raquel’s powerful story and help us raise awareness on behalf of the community.

09/24/2025

Last week, had our first Anchor Week in our new office space. Anchor Weeks bring our hybrid organization together, keeping us connected with our mission and one another. Check out some of the highlights below!

09/19/2025

Amylyx’ SVP of Medical Affairs, Jamie Timmons, MD, is presenting an update on our HELIOS clinical trial in this weekend. Thank you to Wolfram Syndrome UK for having us!

09/12/2025

Amylyx’ Chief Medical Officer Camille Bedrosian, MD, is a panelist at Obesity Science & Innovation here in Boston. See session details below and here: https://informaconnect.com/obesity-science-innovation/agenda/2/

09/11/2025

We care deeply about supporting and investing in our people, and that includes a dedicated focus on Learning and Development through which we offer our employees opportunities to grow professionally and network with others. This week, Amylyx was thrilled to host the Healthcare Businesswomen’s Association New England Exchange Program. Congrats to the 2025 participants, including three members of , and thanks to all who helped make this event a success!

09/03/2025

Wolfram syndrome is a rare, monogenic neurodegenerative disease that progressively impacts multiple organs and systems. There are currently no approved therapies for the approximately 3,000 people in the U.S. living with . Learn more on our website at https://amylyx.com

08/27/2025

Today, we announced the decision to discontinue the ORION program for progressive supranuclear palsy.

We extend our gratitude to the participants, their families and care partners, ORION trial sites, and the entire PSP community for their collaboration on this study. We remain committed to advancing potential new treatments for communities with high unmet needs.

Read more in our press release: https://bit.ly/4fZDl2v

Address

43 Thorndike Street
Cambridge, MA
02141

Website

https://www.amylyx.com/, https://www.amylyx.com/social-media-guidelines

Alerts

Be the first to know and let us send you an email when Amylyx Pharmaceuticals Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Amylyx Pharmaceuticals Inc.:

Want your practice to be the top-listed Clinic in Cambridge?